title: Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme.
abstract: Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.
authors: Department of Neurological Surgery, New York-Presbyterian Hospital, Weill Cornell Medical College, New York 10021, USA.
authors: Jan-Karl
authors: JK
authors: Burkhardt
authors: Benjamin J
authors: BJ
authors: Shin
authors: Cody D
authors: CD
authors: Schlaff
authors: Howard
authors: H
authors: Riina
authors: John A
authors: JA
authors: Boockvar
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D017046:Cost Savings; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000191:economics; D007262:Infusions, Intravenous / Q000191:economics; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab